Institutional investors purchased a net $1.1 million shares of STML during the quarter ended September 2016. This may signal that the smart money is gaining interest in this company as the 49.37% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
APO ASSET MANAGEMENT GMBH Bought 44.0 Thousand shares of Stemline Therapeutics Inc